Letrozol Medical Valley

Letrozole, the active ingredient in Letrozol Medical Valley, is a selective non‑steroidal aromatase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of postmenopausal hormone receptor‑positive breast cancer, helping to reduce estrogen‑driven tumor growth. The product complies with EU regulatory standards and is manufactured under strict quality controls.

GNH USA supplies Letrozol Medical Valley as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozole is used in endocrine therapy targeting estrogen‑dependent breast cancer.

- Postmenopausal hormone receptor‑positive breast cancer: reduces recurrence and disease progression. - Adjuvant therapy after surgery: decreases risk of cancer returning. - Metastatic breast cancer: helps control tumor growth.

Letrozole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hot flashes: transient feeling of warmth and sweating. - Joint and muscle pain: aching in joints or muscles. - Fatigue: persistent tiredness. - Nausea: mild stomach upset. - Headache: mild to moderate pain. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Severe liver injury: elevated liver enzymes or hepatitis. - Bone fracture: increased risk of osteoporosis‑related fractures. - Deep vein thrombosis or pulmonary embolism: clot formation in veins. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Cardiac arrhythmia: QT interval prolongation.

When prescribing letrozole, clinicians should consider several safety precautions.

- Bone health monitoring: assess bone mineral density regularly. - Liver function monitoring: check hepatic enzymes periodically. - Lipid profile monitoring: evaluate cholesterol levels during treatment. - Pregnancy contraindication: avoid use in pregnant women (Category X). - Premenopausal use: not indicated for premenopausal patients. - Store at ambient temperature: keep in original packaging, protect from moisture.

Letrozole can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Tamoxifen: concurrent use may reduce therapeutic effect of both agents. - Estrogen replacement therapy: counteracts letrozole’s action. - Strong CYP2A6 inhibitors (e.g., methoxsalen): may increase letrozole levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may lower letrozole concentrations. - CYP3A4 inhibitors (e.g., ketoconazole): may raise letrozole levels. - Anticoagulants (e.g., warfarin): may increase bleeding risk.